All Articles

The New Public Company Trying To Solve Parkinson’s Disease

August 30, 2023
x min read

AgeX Therapeutics (NYSE: AGE) has announced they will enter into a merger agreement with Serina Therapeutics, a privately held biotechnology company.

The new combined entity is focused on solving an enormous problem: Parkinson’s Disease.


  • AgeX Therapeutics, who is focused on new therapeutics for human aging and longevity, previously invested $10 million into Serina Therapeutics
  • AgeX Therapeutics and Serina Therapeutics will now merge into one combined company
  • The new entity will be called Serina Therapeutics and will trade under the new symbol ‘SER’ once approved

Going deeper:

  • Serina Therapeutics main focus is SER-252, which targets advanced Parkinson’s Disease
  • Currently, SER-252 is in pre clinical studies, with the hope of beginning a Phase I clinical trial next year
  • The problem with many neurological drugs is they need to be dosed frequently, which causes fluctuations in exposure to the drug and can cause challenges for patients
  • What Serina aims to do is provide much more precise control in rate of release in patients and create more stable levels of the drug in patients bloodstreams

Discover what’s next. The world’s biggest ideas, disruptive trends, most exciting early stage companies and groundbreaking entrepreneurs.

By clicking Subscribe you're confirming that you agree with our Privacy Policy.
Thanks for subscribing!
Keep an eye out for a welcome email shortly.
Oops! Something went wrong while submitting the form.